The drug, remdesivir, is an experimental, antiviral therapy that may prevent the virus from reproducing in the patient’s body. The drug has been tested in humans with Ebola. It also has been tested in animals in studies of the Middle Eastern respiratory syndrome, MERS, and severe acute respiratory syndrome, SARS, which are caused by other coronaviruses.
COVID-19 patients enrolled in the clinical trial must be 18 or older and critically ill.
Dr. Thomas Patterson, chief of the Division of Infectious Disease at UT Health, is leading the study at University Hospital, which is among 75 testing sites across the country.
For news media:
Our news team can help you find an expert to interview. Visit our Media Relations page for more information, or call 210-358-2335.